Specialization of the Bulk and Pharmaceutical Businesses
First written in FY2016. 3 of 10 entries say "Restated". Latest entry: FY2022-Q2.
5 other companies' latest entry also says "Achieved".
- FY2022-Q2AchievedAnnual report
「AANG entered into an agreement on 14 April 2021 to transfer all shares of AANE to Metex and completed the transfer on 28 April 2021. At a meeting of the Board of Directors held on 26 April 2021, the company resolved to absorb AANG through a merger, with 1 July 2021 as the effective date. On that date, the company assumed all of AANG's assets, liabilities, rights and obligations.」
The transfer of the European animal nutrition business was completed on 28 April 2021, and AANG was absorbed through a merger on 1 July 2021. This specifically confirms the completion of the business restructuring aimed at becoming asset-light and more specialized. - FY2021AchievedAnnual report
「味の素アニマル・ニュートリション・グループ株式会社, established in 2011, has completed the business restructuring intended to strengthen its organization through integrated global operations, by making the business asset-light and more specialized. Accordingly, there is no longer a compelling need to maintain the separate corporate entity, and the company decided to absorb it through a merger.」
For the animal nutrition business, the company presented a plan to absorb AANG into the company effective 1 July 2021, stating that the business restructuring aimed at becoming asset-light and more specialized had been completed. The transfer of the European business was completed on 28 April 2021. - FY2019AdvancedAnnual report
「(Progress) The company is advancing the shift toward specialty products by expanding the outsourcing of commodity production under a contract manufacturing agreement with China's Meihua Biological Technology Group and suspending its lysine plant in Brazil.」
The company advanced a specific structural transformation by expanding contract production of commodity products and suspending its lysine plant in Brazil. - FY2018AdvancedAnnual report
「Under a global R&D promotion structure, the company is developing new technologies, including low-resource fermentation, to strengthen competitiveness, accelerating industrialization together with overseas technology development centers, and began producing tryptophan in North America in fiscal 2017.」
The company advanced the industrialization of low-resource fermentation and other technologies and began producing tryptophan in North America in fiscal 2017. - FY2018-Q1AdvancedAnnual report
「By entering into this agreement, the company will promote the restructuring of its global supply system for feed-use amino acids, the foundation of its animal nutrition business. From fiscal 2018 onward, the company plans to sell both products manufactured by 梅花社 under its own brand in global markets.」
As part of the structural transformation of the animal nutrition business, the company entered into a specific agreement to outsource production of feed-use lysine and threonine to 梅花社 and sell the products globally under its own brand from fiscal 2018 onward. - FY2017RaisedAnnual report
「The animal nutrition business will accelerate its structural transformation by outsourcing production of commodity products and converting production facilities for specialty products.」
In addition to the previous focus on increasing added value, the company expanded its measures into fundamental business restructuring through outsourcing commodity production and converting production facilities. - FY2017-Q3RestatedAnnual report
「For businesses that continue to face structural challenges, the company will pursue specialization to increase their added value. Specifically, in the bulk business, it will increase the proportion of high-value-added materials, such as the AjiPro®-L lysine formulation for dairy cattle in the animal nutrition business, and raise the proportion of retail products through broad domestic and overseas development of retail products based on taste components and sweetener materials in the processed umami seasonings business.」
The company continues to develop high-value-added materials in animal nutrition, shift processed seasonings toward retail products, and strengthen cost competitiveness through low-resource fermentation. - FY2017-Q2RestatedAnnual report
「For businesses that continue to face structural challenges, the company will pursue specialization to increase their added value. Specifically, in the bulk business, it will increase the proportion of high-value-added materials, such as the AjiPro®-L lysine formulation for dairy cattle in the animal nutrition business, and raise the proportion of retail products through broad domestic and overseas development of retail products based on taste components and sweetener materials in the processed umami seasonings business.」
The company continues to develop high-value-added materials in animal nutrition, shift processed seasonings toward retail products, and strengthen cost competitiveness through low-resource fermentation. - FY2017-Q1RestatedAnnual report
「For businesses that continue to face structural challenges, the company will pursue specialization to increase their added value. Specifically, in the bulk business, it will increase the proportion of high-value-added materials, such as the AjiPro®-L lysine formulation for dairy cattle in the animal nutrition business, and raise the proportion of retail products through broad domestic and overseas development of retail products based on taste components and sweetener materials in the processed umami seasonings business.」
The company continues to develop high-value-added materials in animal nutrition, shift processed seasonings toward retail products, and strengthen cost competitiveness through low-resource fermentation. - FY2016First statedAnnual report
「For businesses that continue to face structural challenges, the company will pursue specialization to increase their added value.」
The policy is to focus animal nutrition on high-value-added materials, processed umami seasonings on retail products, and pharmaceuticals on the gastroenterology field.